Maarten Groenink
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Maarten Groenink has a total of 222 co-authors. Here are the top co-authors by number of shared publications:
- Barbara J. M. Mulder
Center for Congenital Heart Disease Amsterdam-Leiden (CAHAL), Department of Clinical and Experimental Cardiology, Amsterdam Cardiovascular Sciences, Heart Centre, Amsterdam UMC, University of Amsterdam, 1105 AZ Amsterdam, The Netherlands
9 shared publications Aeilko H. Zwinderman
Department of Clinical Epidemiology and Biostatistics, Academic Medical Centre, Amsterdam, The Netherlands
5 shared publications- Romy Franken
Department of Cardiology, Academic Medical Center, Amsterdam, the Netherlands; Interuniversity Cardiology Institute of the Netherlands, Utrecht, the Netherlands
5 shared publications Arthur J. Scholte
Department of Cardiology, Leiden University Medical Centre, The Netherlands
4 shared publications- Berto Jorrit Bouma
Department of Cardiology Amsterdam University Medical Centre Amsterdam The Netherlands
4 shared publications Janneke Timmermans
Department of Cardiology, Radboud University Nijmegen Medical Centre, The Netherlands
4 shared publications
Latest Publications
- Top Cited PapersOpen Access
- 29 August 2022
- Published by Elsevier in The Lancet
- Vol. 400 (10355) , 822-831
Angiotensin receptor blockers and β blockers in Marfan syndrome: an individual patient data meta-analysis of randomised trials
- 29 August 2022
- Published by Elsevier in The Lancet
- Vol. 400 (10355) , 822-831
Top Cited PapersOpen AccessAngiotensin receptor blockers and β blockers in Marfan syndrome: an individual patient data meta-analysis of randomised trials
- Open Access
Aortic root in competitive sports: eyes on the older athlete
Individuals with a suspicion of aortic disease are discouraged to take part in most competitive sports.1 In the more prevalent and syndromic forms, such as Marfan syndrome (prevalence 1: 5000), a sports examination with echocardiography may reveal this condition, with great consequences for the fate (and especially career) of a young athlete. From the point of view of the most recent guidelines,1 2 the prevention of aortic dissection is emphasised as the main task of clinicians. Cut-off values and z-scores are supplied to identify those that could be at risk for a pathophysiological process leading to cardiovascular morbidity and mortality. At the same time, sports physicians are often struggling with the cases that may be less clear, where slight aortic dilatation may be considered physiological. While the initial steps are evident—thoroughly investigate if there are any signs of underlying diseases such as Marfan syndrome or related conditions—in individuals with a mild dilatation of the aortic root without any other signs of an underlying disease, the next steps to be taken can be less clear. The increased availability of genetic panels to detect inborn predispositions for a wide range of aortic disorders may tempt …
Open AccessAortic root in competitive sports: eyes on the older athlete
Individuals with a suspicion of aortic disease are discouraged to take part in most competitive sports.1 In the more prevalent and syndromic forms, such as Marfan syndrome (prevalence 1: 5000), a sports examination with echocardiography may reveal this condition, with great consequences for the fate (and especially career) of a young athlete. From the point of view of the most recent guidelines,1 2 the prevention of aortic dissection is emphasised as the main task of clinicians. Cut-off values and z-scores are supplied to identify those that could be at risk for a pathophysiological process leading to cardiovascular morbidity and mortality. At the same time, sports physicians are often struggling with the cases that may be less clear, where slight aortic dilatation may be considered physiological. While the initial steps are evident—thoroughly investigate if there are any signs of underlying diseases such as Marfan syndrome or related conditions—in individuals with a mild dilatation of the aortic root without any other signs of an underlying disease, the next steps to be taken can be less clear. The increased availability of genetic panels to detect inborn predispositions for a wide range of aortic disorders may tempt …
- Open Access
- 5 March 2019
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 20 (5) , 1122
The Potential Beneficial Effects of Resveratrol on Cardiovascular Complications in Marfan Syndrome Patients–Insights from Rodent-Based Animal Studies
Marfan syndrome (MFS) patients are at risk for cardiovascular disease. In particular, for aortic aneurysm formation, which ultimately can result in a life-threatening aortic dissection or rupture. Over the years, research into a sufficient pharmacological treatment option against aortopathy has expanded, mostly due to the development of rodent disease models for aneurysm formation and dissections. Unfortunately, no optimal treatment strategy has yet been identified for MFS. The biologically-potent polyphenol resveratrol (RES), that occurs in nuts, plants, and the skin of grapes, was shown to have a positive effect on aortic repair in various rodent aneurysm models. RES demonstrated to affect aortic integrity and aortic dilatation. The beneficial processes relevant for MFS included the improvement of endothelial dysfunction, extracellular matrix degradation, and smooth muscle cell death. For the wide range of beneficial effects on these mechanisms, evidence was found for the following involved pathways; alleviating oxidative stress (change in eNOS/iNOS balance and decrease in NOX4), reducing protease activity to preserve the extracellular matrix (decrease in MMP2), and improving smooth muscle cell survival affecting aortic aging (changing the miR21/miR29 balance). Besides aortic features, MFS patients may also suffer from manifestations concerning the heart, such as mitral valve prolapse and left ventricular impairment, where evidence from rodent models shows that RES may aid in promoting cardiomyocyte survival directly (SIRT1 activation) or by reducing oxidative stress (increasing superoxide dismutase) and increasing autophagy (AMPK activation). This overview discusses recent RES studies in animal models of aortic aneurysm formation and heart failure, where different advantageous effects have been reported that may collectively improve the aortic and cardiac pathology in patients with MFS. Therefore, a clinical study with RES in MFS patients seems justified, to validate RES effectiveness, and to judge its suitability as potential new treatment strategy.
- 5 March 2019
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 20 (5) , 1122
Open AccessThe Potential Beneficial Effects of Resveratrol on Cardiovascular Complications in Marfan Syndrome Patients–Insights from Rodent-Based Animal Studies
Marfan syndrome (MFS) patients are at risk for cardiovascular disease. In particular, for aortic aneurysm formation, which ultimately can result in a life-threatening aortic dissection or rupture. Over the years, research into a sufficient pharmacological treatment option against aortopathy has expanded, mostly due to the development of rodent disease models for aneurysm formation and dissections. Unfortunately, no optimal treatment strategy has yet been identified for MFS. The biologically-potent polyphenol resveratrol (RES), that occurs in nuts, plants, and the skin of grapes, was shown to have a positive effect on aortic repair in various rodent aneurysm models. RES demonstrated to affect aortic integrity and aortic dilatation. The beneficial processes relevant for MFS included the improvement of endothelial dysfunction, extracellular matrix degradation, and smooth muscle cell death. For the wide range of beneficial effects on these mechanisms, evidence was found for the following involved pathways; alleviating oxidative stress (change in eNOS/iNOS balance and decrease in NOX4), reducing protease activity to preserve the extracellular matrix (decrease in MMP2), and improving smooth muscle cell survival affecting aortic aging (changing the miR21/miR29 balance). Besides aortic features, MFS patients may also suffer from manifestations concerning the heart, such as mitral valve prolapse and left ventricular impairment, where evidence from rodent models shows that RES may aid in promoting cardiomyocyte survival directly (SIRT1 activation) or by reducing oxidative stress (increasing superoxide dismutase) and increasing autophagy (AMPK activation). This overview discusses recent RES studies in animal models of aortic aneurysm formation and heart failure, where different advantageous effects have been reported that may collectively improve the aortic and cardiac pathology in patients with MFS. Therefore, a clinical study with RES in MFS patients seems justified, to validate RES effectiveness, and to judge its suitability as potential new treatment strategy.
- 9 May 2017
- Published by Wolters Kluwer Health in Circulation
- Vol. 135 (19) , 1873-1875
Impact of Structural Cerebral Damage in Adults With Tetralogy of Fallot
- 9 May 2017
- Published by Wolters Kluwer Health in Circulation
- Vol. 135 (19) , 1873-1875
Impact of Structural Cerebral Damage in Adults With Tetralogy of Fallot
- Open Access
- 4 October 2016
- Published by Springer Nature in Netherlands Heart Journal
- Vol. 24 (11) , 675-681
The effect of losartan therapy on ventricular function in Marfan patients with haploinsufficient or dominant negative FBN1 mutations
- 4 October 2016
- Published by Springer Nature in Netherlands Heart Journal
- Vol. 24 (11) , 675-681
Open AccessThe effect of losartan therapy on ventricular function in Marfan patients with haploinsufficient or dominant negative FBN1 mutations
- 1 September 2015
- Published by Elsevier in International Journal of Cardiology
- Vol. 194, 7-12
Increased aortic tortuosity indicates a more severe aortic phenotype in adults with Marfan syndrome
- 1 September 2015
- Published by Elsevier in International Journal of Cardiology
- Vol. 194, 7-12
Increased aortic tortuosity indicates a more severe aortic phenotype in adults with Marfan syndrome
- 1 December 2014
- Published by Elsevier in International Journal of Cardiology
- Vol. 177 (2) , e70-e71
Computed tomography coronary angiography should be performed in all patients with Marfan Syndrome prior to aortic root replacement
- 1 December 2014
- Published by Elsevier in International Journal of Cardiology
- Vol. 177 (2) , e70-e71
Computed tomography coronary angiography should be performed in all patients with Marfan Syndrome prior to aortic root replacement
- 1 November 2013
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 269 (2) , 370-377
Aortic Disease in Patients with Marfan Syndrome: Aortic Volume Assessment for Surveillance
Total aortic volume measurement is a highly reproducible method that may be useful for surveillance of global aortic expansion in patients with Marfan syndrome. PurposeTo assess the reproducibility of aortic volume estimates and to serially test their use in patients with Marfan syndrome.Materials and MethodsThe study was approved by the medical ethics committee and all subjects gave written informed consent. In 81 patients with Marfan syndrome and seven healthy control subjects, aortic volumes and diameters at baseline were estimated by means of contrast material–enhanced magnetic resonance (MR) imaging. At 3 years of follow-up, aortic expansion rate were calculated in a subgroup of 22 patients with Marfan syndrome. Total aortic volume was defined as volume measurement from the level of the aortic annulus to the aortic bifurcation. Intra- and interobserver agreement of aortic volume were calculated by using the intraclass correlation coefficient. Differences in variables were analyzed with the Student t test and logistic regression. Effect size was calculated.ResultsIntra- and interobserver agreement of aortic volume calculation was 0.996 and 0.980, respectively...
- 1 November 2013
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 269 (2) , 370-377
Aortic Disease in Patients with Marfan Syndrome: Aortic Volume Assessment for Surveillance
Total aortic volume measurement is a highly reproducible method that may be useful for surveillance of global aortic expansion in patients with Marfan syndrome. PurposeTo assess the reproducibility of aortic volume estimates and to serially test their use in patients with Marfan syndrome.Materials and MethodsThe study was approved by the medical ethics committee and all subjects gave written informed consent. In 81 patients with Marfan syndrome and seven healthy control subjects, aortic volumes and diameters at baseline were estimated by means of contrast material–enhanced magnetic resonance (MR) imaging. At 3 years of follow-up, aortic expansion rate were calculated in a subgroup of 22 patients with Marfan syndrome. Total aortic volume was defined as volume measurement from the level of the aortic annulus to the aortic bifurcation. Intra- and interobserver agreement of aortic volume were calculated by using the intraclass correlation coefficient. Differences in variables were analyzed with the Student t test and logistic regression. Effect size was calculated.ResultsIntra- and interobserver agreement of aortic volume calculation was 0.996 and 0.980, respectively...